RecruitingNot Applicable

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

India100 participantsStarted 2022-07-28

Plain-language summary

This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.

Age range0 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp
✓. Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records

Major Structural Defects

Timeframe: From Brexafemme exposure up to one year after birth

NCT IDNCT05908682

SponsorScynexis, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-10-31

Sanjeev Miglani, MD